Razelle Kurzrock: DART hits the target again
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared a post by Young Kwang Chae, Associate Professor of Medicine, medical oncologist, and physician-scientist at Northwestern University’s Feinberg School of Medicine, on X, adding:
“DART hits the target again.
Non epithelial ovarian cancer. Another very rare cancer. In addition to 2 responses lasting >4 years, there was a patient with stable disease for over 30 months. Nivo + low-dose ipi.
Congrats to our team Young Kwang Chae and Sandip Patel.”
Quoting Young Kwang Chae‘s post:
“Go SWOG DART team! Our new publication in CCR! Nivo/ipi can be effective in select non-epithelial ovarian cancer (granulosa cell tumor, ORR 25%, 1CR&1PR/8, lasting >4 years).”
SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Authors: Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea, John M. Schallenkamp, Nabil Adra, Leonard J. Appleman, Mitchell Alden, Jessica Thomes Pepin, John A. Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M. Rampurwala, William R. Robinson, Hye Sung Kim, Liam IL-Young Chung, Christine M. McLeod, Gabby Lopez, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
More posts featuring Razelle Kurzrock.
Young Kwang Chae is an Associate Professor of Medicine, medical oncologist, and physician-scientist at Northwestern University’s Feinberg School of Medicine. His work focuses on personalized cancer therapy and precision medicine, with expertise in early-phase clinical trials, first-in-human studies, novel combination therapies, targeted therapy, and immunotherapy.
Razelle Kurzrock, MD, is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy.
She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine). She also developed and led some of the first tumor-agnostic cancer clinical trials.
During her time at the University of California San Diego Health, Dr. Kurzrock’s charge was founding and leading the Center for Personalized Cancer Therapy as well as the Experimental Therapeutics program, and she also founded a Rare Tumor Clinic focused on precision medicine.
The signature study of the center was the I-PREDICT study (Nature Medicine, 2019) that gave, for the first time, individualized N-of-1 matched combination therapies to patients with lethal malignancies, hence resulting in improved outcomes, and transforming the entire paradigm for oncology treatment. This work was presented at the Nobel Symposium, Karolinska Institute, Stockholm, Sweden in September 2023.
Dr Kurzrock has performed key early-phase studies of 8 drugs that have gone on to FDA approval. Many of her studies have also been incorporated into NCCN guidelines.Dr. Kurzrock is also an entrepreneur. She is co-founder of CureMatch, and on the Board of CureMetrix, CureMatch, and Xcures.
Dr. Kurzrock is the author of >1000 peer-reviewed articles on PubMed and has a highly exceptional Hirsch index (h-index) score of 147, with over almost 100,000 citations. She has been selected each year since 2019 as one of the world’s most cited scientists worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023